Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPS: High-dose vs Standard-dose Imatinib in CML-CP
NCT00124748Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jun 2005
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of imatinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoint: Major Molecular Response at 12 months. Started Jun 2005; status: terminated.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00124748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124748.